Cantargia AB (FRA:7V3)

Q1 2026 Cantargia AB Earnings Call Transcript

May 19, 2026 / 01:00 PM GMT

Release Date Price: €0.2794 (-0.92%)

Transcript

Key Points

Positve

Cantargia AB (FRA:7V3) is refining its development focus in PDAC, with a clear opportunity for nanolimob in combination settings.
The company has received encouraging signals from the MD Anderson study in MDS, supporting the potential of IL-1RAP in hematologic malignancies.
Nadnulumab has gained momentum with new data in the MDS-AML study, adding a second clinical opportunity.
The company is advancing a broader discovery engine for next-generation IL-1RAP-based therapies.
Cantargia AB (FRA:7V3) has a financial profile aligned with advancing key programs while maintaining discipline.

Negative

Cantargia AB (FRA:7V3) reported a loss of CHK33 million for Q1 2026, with earnings per share at CHK13.13.
The company does not expect any milestone payments related to the Kanten transaction for fiscal 2026.
There is uncertainty regarding the initiation of a Phase 3 program in pancreatic cancer due to evolving treatment paradigms.
The company faces challenges in securing early access to study drugs for combination studies.
The initial promising results in MDS are based on a small patient population, requiring further validation.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CANTA.ST - Cantargia AB
Q1 2026 Cantargia AB Earnings Call
May 19, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Candorja Q1 Report 2026 presentation. During the Q&A session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to the speakers, CEO Hild Steiniger and CFO Patrek Remblad. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good afternoon, everyone, and thank you for joining us. I am Hilde Steiniger, CEO of Kantargia.

Today, I will present our Q1 2026 update and progress across all our I-1 platform, including how we are adapting our oncology strategy to an evolving treatment

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.